BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31393228)

  • 1. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
    Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
    Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
    [No Abstract]   [Full Text] [Related]  

  • 2. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
    Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Klf10 Gene, a Secondary Modifier and a Pharmacogenomic Biomarker of Hydroxyurea Treatment Among Patients With Hemoglobinopathies.
    Elalfy MS; El Sherif NH; Kamal TM; Aly NH
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):e155-e162. PubMed ID: 28085748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
    Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
    Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
    Tafrali C; Paizi A; Borg J; Radmilovic M; Bartsakoulia M; Giannopoulou E; Giannakopoulou O; Stojiljkovic-Petrovic M; Zukic B; Poulas K; Stavrou EF; Lambropoulou P; Kourakli A; Felice AE; Papachatzopoulou A; Philipsen S; Pavlovic S; Georgitsi M; Patrinos GP
    Pharmacogenomics; 2013 Apr; 14(5):469-83. PubMed ID: 23556445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.
    Chondrou V; Stavrou EF; Markopoulos G; Kouraklis-Symeonidis A; Fotopoulos V; Symeonidis A; Vlachaki E; Chalkia P; Patrinos GP; Papachatzopoulou A; Sgourou A
    Hum Genomics; 2018 Oct; 12(1):45. PubMed ID: 30285874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.
    Gravia A; Chondrou V; Sgourou A; Papantoni I; Borg J; Katsila T; Papachatzopoulou A; Patrinos GP
    Pharmacogenomics; 2014 Jul; 15(10):1355-64. PubMed ID: 25155936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients.
    Chondrou V; Kolovos P; Sgourou A; Kourakli A; Pavlidaki A; Kastrinou V; John A; Symeonidis A; Ali BR; Papachatzopoulou A; Katsila T; Patrinos GP
    Hum Genomics; 2017 Oct; 11(1):24. PubMed ID: 29061162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.
    Chalikiopoulou C; Tavianatou AG; Sgourou A; Kourakli A; Kelepouri D; Chrysanthakopoulou M; Kanelaki VK; Mourdoukoutas E; Siamoglou S; John A; Symeonidis A; Ali BR; Katsila T; Papachatzopoulou A; Patrinos GP
    Pharmacogenomics; 2016 Mar; 17(4):393-403. PubMed ID: 26895070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies.
    Patrinos GP; Chui DHK; Hardison RC; Steinberg MH
    Expert Rev Hematol; 2021 Oct; 14(10):883-885. PubMed ID: 34490838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies.
    Perrine SP; Pace BS; Faller DV
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):233-48. PubMed ID: 24589264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
    Pecoraro A; Troia A; Calzolari R; Scazzone C; Rigano P; Martorana A; Sacco M; Maggio A; Di Marzo R
    Hemoglobin; 2015; 39(4):225-9. PubMed ID: 26016899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of SIN3A genomic variants with β-hemoglobinopathies disease severity and hydroxyurea treatment efficacy.
    Gravia A; Chondrou V; Kolliopoulou A; Kourakli A; John A; Symeonidis A; Ali BR; Sgourou A; Papachatzopoulou A; Katsila T; Patrinos GP
    Pharmacogenomics; 2016 Nov; 17(16):1785-1793. PubMed ID: 27767389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study on the Role of Polymorphisms of the SOX-6 and MYB Genes and Fetal Hemoglobin Levels in Sicilian Patients with β-Thalassemia and Sickle Cell Disease.
    Listì F; Sclafani S; Agrigento V; Barone R; Maggio A; D'Alcamo E
    Hemoglobin; 2018 Mar; 42(2):103-107. PubMed ID: 30200835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia.
    Fibach E; Burke LP; Schechter AN; Noguchi CT; Rodgers GP
    Blood; 1993 Mar; 81(6):1630-5. PubMed ID: 7680923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting fetal hemoglobin expression to treat β hemoglobinopathies.
    Steinberg MH
    Expert Opin Ther Targets; 2022 Apr; 26(4):347-359. PubMed ID: 35418266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
    Lai ZS; Yeh TK; Chou YC; Hsu T; Lu CT; Kung FC; Hsieh MY; Lin CH; Chen CT; James Shen CK; Jiaang WT
    Eur J Med Chem; 2021 Jan; 209():112938. PubMed ID: 33109398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.